Shokouh Arjmand, Mehran Ilaghi, Ali Karimi Sisakht, Matti Bock Guldager, Gregers Wegener, Anne M. Landau, Albert Gjedde
{"title":"Regulation of mitochondrial dysfunction by estrogens and estrogen receptors in Alzheimer's disease: A focused review","authors":"Shokouh Arjmand, Mehran Ilaghi, Ali Karimi Sisakht, Matti Bock Guldager, Gregers Wegener, Anne M. Landau, Albert Gjedde","doi":"10.1111/bcpt.14035","DOIUrl":null,"url":null,"abstract":"<p>Alzheimer's disease (AD) is a neurodegenerative disorder that primarily manifests itself by progressive memory loss and cognitive decline, thus significantly affecting memory functions and quality of life. In this review, we proceed from the understanding that the canonical amyloid-β hypothesis, while significant, has faced setbacks, highlighting the need to adopt a broader perspective considering the intricate interplay of diverse pathological pathways for effective AD treatments. Sex differences in AD offer valuable insights into a better understanding of its pathophysiology. Fluctuation of the levels of ovarian sex hormones during perimenopause is associated with changes in glucose metabolism, as a possible window of opportunity to further understand the roles of sex steroid hormones and their associated receptors in the pathophysiology of AD. We review these dimensions, emphasizing the potential of estrogen receptors (ERs) to reveal mitochondrial functions in the search for further research and therapeutic strategies for AD pharmacotherapy. Understanding and addressing the intricate interactions of mitochondrial dysfunction and ERs potentially pave the way for more effective approaches to AD therapy.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 2","pages":"115-132"},"PeriodicalIF":2.7000,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14035","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcpt.14035","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that primarily manifests itself by progressive memory loss and cognitive decline, thus significantly affecting memory functions and quality of life. In this review, we proceed from the understanding that the canonical amyloid-β hypothesis, while significant, has faced setbacks, highlighting the need to adopt a broader perspective considering the intricate interplay of diverse pathological pathways for effective AD treatments. Sex differences in AD offer valuable insights into a better understanding of its pathophysiology. Fluctuation of the levels of ovarian sex hormones during perimenopause is associated with changes in glucose metabolism, as a possible window of opportunity to further understand the roles of sex steroid hormones and their associated receptors in the pathophysiology of AD. We review these dimensions, emphasizing the potential of estrogen receptors (ERs) to reveal mitochondrial functions in the search for further research and therapeutic strategies for AD pharmacotherapy. Understanding and addressing the intricate interactions of mitochondrial dysfunction and ERs potentially pave the way for more effective approaches to AD therapy.
阿尔茨海默病(AD)是一种神经退行性疾病,主要表现为进行性记忆丧失和认知能力下降,从而严重影响记忆功能和生活质量。在这篇综述中,我们认为经典的淀粉样蛋白-β假说虽然意义重大,但却面临挫折,这凸显了我们需要从更广阔的视角来考虑各种病理途径错综复杂的相互作用,从而有效地治疗阿兹海默症。AD的性别差异为更好地理解其病理生理学提供了宝贵的见解。围绝经期卵巢性激素水平的波动与葡萄糖代谢的变化有关,这可能是进一步了解性类固醇激素及其相关受体在AD病理生理学中的作用的机会之窗。我们回顾了这些方面,强调了雌激素受体(ER)揭示线粒体功能的潜力,以寻求进一步的研究和 AD 药物治疗策略。了解和解决线粒体功能障碍与雌激素受体之间错综复杂的相互作用,有可能为更有效的AD治疗方法铺平道路。
期刊介绍:
Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.